Respiratory Tract Neoplasms  >>  Caprelsa (vandetanib)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
ZODIAC, NCT00312377 / 2005-004749-32: ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Checkmark +docetaxel, 2nd line
Jul 2014 - Jul 2014: +docetaxel, 2nd line
Completed
3
1690
Japan, US, Canada, Europe, RoW
Docetaxel, TAXOTERE™, Vandetanib, ZACTIMA™, ZD6474
Genzyme, a Sanofi Company
Non-small Cell Lung Cancer, Lung Cancer
08/08
03/14
NCT00364351 / 2006-000259-16: Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Checkmark Data
Feb 2011 - Feb 2011: Data
Completed
3
1574
US, Canada, Europe, RoW
Vandetanib, ZD6474, ZACTIMA™, Erlotinib, Tarceva®
Genzyme, a Sanofi Company
Non Small Cell Lung Cancer
09/08
11/16
NCT00404924 / 2006-002384-12: ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Checkmark P3 data (NSCLC) ZEPHYR
Mar 2012 - Mar 2012: P3 data (NSCLC) ZEPHYR
Completed
3
1140
US, Canada, Europe, RoW
ZD6474 (vandetanib), ZACTIMA™, Best Supportive Care
Genzyme, a Sanofi Company
Non-Small-Cell Lung Carcinoma
10/09
11/14

Download Options